FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590350007> ?p ?o ?g. }

• W2590350007 endingPage "975" @default.
• W2590350007 startingPage "962" @default.
• W2590350007 abstract "Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8+ effector cells acutely following VSV therapy with markedly high expression of the immune checkpoint molecules PD-1 and TIM-3. Using these data, we tested a treatment schedule incorporating mAb immune checkpoint inhibitors with VSV+ACT treatment. Unlike clinical scenarios, we delivered therapy at early time points following tumor establishment and treatment. Our goal was to potentiate the immune response generated by VSV therapy to achieve durable control of metastatic disease. Despite the high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells following virus administration, antibody blockade did not improve survival. These findings provide highly significant information about response kinetics to viroimmunotherapy and juxtapose the clinical use of checkpoint inhibitors against chronically dysfunctional T cells and the acute T cell response to oncolytic viruses. Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8+ effector cells acutely following VSV therapy with markedly high expression of the immune checkpoint molecules PD-1 and TIM-3. Using these data, we tested a treatment schedule incorporating mAb immune checkpoint inhibitors with VSV+ACT treatment. Unlike clinical scenarios, we delivered therapy at early time points following tumor establishment and treatment. Our goal was to potentiate the immune response generated by VSV therapy to achieve durable control of metastatic disease. Despite the high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells following virus administration, antibody blockade did not improve survival. These findings provide highly significant information about response kinetics to viroimmunotherapy and juxtapose the clinical use of checkpoint inhibitors against chronically dysfunctional T cells and the acute T cell response to oncolytic viruses." @default.
• W2590350007 created "2017-03-03" @default.
• W2590350007 creator A5018017760 @default.
• W2590350007 creator A5022285180 @default.
• W2590350007 creator A5048427923 @default.
• W2590350007 creator A5052140429 @default.
• W2590350007 creator A5056252759 @default.
• W2590350007 creator A5067715117 @default.
• W2590350007 creator A5070554485 @default.
• W2590350007 creator A5071498156 @default.
• W2590350007 creator A5082704917 @default.
• W2590350007 creator A5086024885 @default.
• W2590350007 creator A5091490493 @default.
• W2590350007 date "2017-04-01" @default.
• W2590350007 modified "2023-09-26" @default.
• W2590350007 title "Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy" @default.
• W2590350007 cites W1678412754 @default.
• W2590350007 cites W1936207051 @default.
• W2590350007 cites W1959677146 @default.
• W2590350007 cites W1985182657 @default.
• W2590350007 cites W1985582416 @default.
• W2590350007 cites W1988555834 @default.
• W2590350007 cites W1993686673 @default.
• W2590350007 cites W2008620560 @default.
• W2590350007 cites W2039123767 @default.
• W2590350007 cites W2058016035 @default.
• W2590350007 cites W2088594694 @default.
• W2590350007 cites W2089258482 @default.
• W2590350007 cites W2095786128 @default.
• W2590350007 cites W2098772563 @default.
• W2590350007 cites W2107598346 @default.
• W2590350007 cites W2109274792 @default.
• W2590350007 cites W2114238926 @default.
• W2590350007 cites W2115955652 @default.
• W2590350007 cites W2127283062 @default.
• W2590350007 cites W2137990420 @default.
• W2590350007 cites W2144256523 @default.
• W2590350007 cites W2149121521 @default.
• W2590350007 cites W2166662937 @default.
• W2590350007 cites W2170739773 @default.
• W2590350007 cites W2190678841 @default.
• W2590350007 cites W2199953088 @default.
• W2590350007 cites W2207230085 @default.
• W2590350007 cites W2318212002 @default.
• W2590350007 cites W2320605421 @default.
• W2590350007 cites W2345883861 @default.
• W2590350007 cites W2514996992 @default.
• W2590350007 cites W2572174216 @default.
• W2590350007 cites W2592935721 @default.
• W2590350007 doi "https://doi.org/10.1016/j.ymthe.2017.01.023" @default.
• W2590350007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5383647" @default.
• W2590350007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28237836" @default.
• W2590350007 hasPublicationYear "2017" @default.
• W2590350007 type Work @default.
• W2590350007 sameAs 2590350007 @default.
• W2590350007 citedByCount "21" @default.
• W2590350007 countsByYear W25903500072017 @default.
• W2590350007 countsByYear W25903500072018 @default.
• W2590350007 countsByYear W25903500072019 @default.
• W2590350007 countsByYear W25903500072020 @default.
• W2590350007 countsByYear W25903500072021 @default.
• W2590350007 countsByYear W25903500072022 @default.
• W2590350007 countsByYear W25903500072023 @default.
• W2590350007 crossrefType "journal-article" @default.
• W2590350007 hasAuthorship W2590350007A5018017760 @default.
• W2590350007 hasAuthorship W2590350007A5022285180 @default.
• W2590350007 hasAuthorship W2590350007A5048427923 @default.
• W2590350007 hasAuthorship W2590350007A5052140429 @default.
• W2590350007 hasAuthorship W2590350007A5056252759 @default.
• W2590350007 hasAuthorship W2590350007A5067715117 @default.
• W2590350007 hasAuthorship W2590350007A5070554485 @default.
• W2590350007 hasAuthorship W2590350007A5071498156 @default.
• W2590350007 hasAuthorship W2590350007A5082704917 @default.
• W2590350007 hasAuthorship W2590350007A5086024885 @default.
• W2590350007 hasAuthorship W2590350007A5091490493 @default.
• W2590350007 hasBestOaLocation W25903500071 @default.
• W2590350007 hasConcept C147483822 @default.
• W2590350007 hasConcept C159047783 @default.
• W2590350007 hasConcept C167672396 @default.
• W2590350007 hasConcept C193419808 @default.
• W2590350007 hasConcept C203014093 @default.
• W2590350007 hasConcept C2522874641 @default.
• W2590350007 hasConcept C2776090121 @default.
• W2590350007 hasConcept C2777701055 @default.
• W2590350007 hasConcept C2779057330 @default.
• W2590350007 hasConcept C2780851360 @default.
• W2590350007 hasConcept C502942594 @default.
• W2590350007 hasConcept C82210918 @default.
• W2590350007 hasConcept C86803240 @default.
• W2590350007 hasConcept C8891405 @default.
• W2590350007 hasConcept C90375314 @default.
• W2590350007 hasConceptScore W2590350007C147483822 @default.
• W2590350007 hasConceptScore W2590350007C159047783 @default.
• W2590350007 hasConceptScore W2590350007C167672396 @default.
• W2590350007 hasConceptScore W2590350007C193419808 @default.
• W2590350007 hasConceptScore W2590350007C203014093 @default.
• W2590350007 hasConceptScore W2590350007C2522874641 @default.
• W2590350007 hasConceptScore W2590350007C2776090121 @default.

• next